tuneTypical Dose
2-10 mg per day
Natural Compound
Capsaicin
8-Methyl-N-vanillyl-6-nonenamide (from Capsicum)
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Acute metabolic effects within ~1 hour. Topical pain relief over 1-2 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Capsaicin is the pungent chili compound that activates TRPV1 receptors. It is used topically for neuropathic pain and orally for small thermogenic and appetite effects.
Topical capsaicin has the clearest human evidence, with newer pooled data supporting short-term osteoarthritis pain relief despite frequent local burning. Oral capsinoids may still modestly raise energy expenditure and reduce appetite, but those effects are smaller and less durable than the topical analgesic signal. Practical value depends heavily on formulation and tolerance, especially application-site burning or GI irritation.
TRPV1 agonism increases catecholamine/sympathetic signaling for thermogenesis and depletes Substance P via topical TRPV1 desensitization for pain relief.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- topical pain relief (neuropathic)
- fat oxidation
- metabolic rate
Secondary Outcomes
- appetite suppression (pre-meal use)
Safety
Contraindications and Interactions
Contraindications
- GI ulcers
- IBS (oral)
- Broken skin (topical)
Side effects
- Burning sensation (topical and oral)
- GI irritation/burning (mouth or abdomen) with oral use
- Skin redness/itching at application site
- Flushing or sweating
- Cough
- Eye irritation with accidental contact
- Hypertension (rare, reported after very high pepper intake)
Interactions
- ACE inhibitors (may worsen cough)
- Anticoagulants/antiplatelet drugs (possible additive bleeding risk, preclinical evidence)
- Acetylsalicylic acid/aspirin (possible reduced bioavailability, animal data)
- Theophylline (possible increased absorption)
- Simvastatin (possible reduced concentrations, animal data)
- Galantamine (possible reduced concentrations, animal data)
- CYP2C19 substrate drugs (possible metabolism inhibition, preclinical)
- CYP3A4 substrate drugs (mixed preclinical effects on metabolism)
- P-glycoprotein substrate drugs (possible transporter modulation, preclinical)
- Ciprofloxacin (possible increased bioavailability, rat data)
Avoid if
- Active GI ulceration
- Severe IBS (oral use)
- Broken or inflamed skin at application site (topical use)
- Pregnancy unless clinician-guided
- Lactation unless clinician-guided
Evidence
Study-level References
capsaicin-SRC-001Systematic review and meta-analysis
Sourceopen_in_newTshering G, Posadzki P, Kongkaew C. Efficacy and safety of topical capsaicin in the treatment of osteoarthritis pain: A systematic review and meta-analysis. Phytother Res. 2024;38(7):3695-3705. doi:10.1002/ptr.8223. PMID:38761115.
Population: Adults with osteoarthritis enrolled in topical capsaicin randomized controlled trials.
Dose protocol: Topical capsaicin 0.0125% to 5% across osteoarthritis RCTs
Key findings: Meta-analysis showed lower pain scores versus placebo, but burning sensation increased markedly and evidence certainty remained low to very low.
Notes: This is the best modern anchor for keeping the topical-pain claim and narrowing oral-weight-loss overreach.
Paper content
Topical capsaicin reduced osteoarthritis pain versus placebo in pooled randomized trials, but burning at the application site was common and evidence certainty remained low to very low. This is a good modernization source because it supports short-term use while keeping tolerability front and center.